Propeller Health said today that it won 510(k) clearance from the FDA to market its Propeller platform with GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler. A sensor for the dry powder inhaler was built as a part of a 1 year-long development and R&D collaboration between Propeller and GSK.
This marks the 8th clearance for Propeller’s connected inhaler platform.
The Madison, Wisconsin-based company won CE Mark approval and Health Canada registration for the use of its connected platform with the Ellipta inhaler earlier this year.
Get the full story at our sister site, Drug Delivery Business News.
The post Propeller wins FDA nod for connected GSK Ellipta inhaler appeared first on MassDevice.